Ocugen Inc Stock Price, News & Analysis

Ocugen has submitted an Investigational New Drug (IND) application to the FDA for initiating a Phase 1 clinical trial of OCU200, aimed at treating diabetic macular edema (DME). This milestone represents a commitment to addressing unmet medical needs in ocular disease treatment. DME affects about 745,000 individuals in the U.S., with expectations for this number to rise alongside diabetes prevalence. The Phase 1 trial will focus on the unilateral administration of OCU200, alone or with anti-VEGF therapy. Additionally, Ocugen plans to explore OCU200's potential for treating diabetic retinopathy and wet age-related macular degeneration, impacting around 10 million patients.

Ocugen, Inc. (NASDAQ: OCGN) announced that Chief Scientific Officer Arun Upadhyay will speak at the Retinal Vascular Disease Drug Development Summit from February 21-23, 2023, in Boston. Dr. Upadhyay's presentation, scheduled for February 23 at 1:30 p.m. ET, will focus on developing a novel therapeutic for diabetic macular edema (DME) patients who do not respond to current treatments. Ocugen is advancing OCU200, a new fusion protein aimed at treating severe retinal diseases, and is planning to submit an IND application in Q1 2023. This initiative reflects the company's commitment to addressing unmet medical needs in retinal disease therapy.

Ocugen, Inc. (NASDAQ: OCGN) announced that it will host a conference call and live webcast to discuss its fourth quarter and full year 2022 financial results on February 28, 2023, at 8:30 a.m. ET. A pre-market earnings announcement will also be released on the same day. The conference call can be accessed through provided dial-in numbers and a webcast link available on the company's investor site. A replay of the call will be available for approximately 45 days post-event. Ocugen focuses on developing novel gene and cell therapies, with a particular emphasis on addressing unmet medical needs.

Ocugen, Inc. (NASDAQ: OCGN) has appointed Quan A. Vu as Chief Business Officer, effective February 1, 2023. Vu brings 20 years of healthcare business experience, with a focus on corporate and business development. He will lead efforts to expand Ocugen's product portfolio and secure new business partnerships. Dr. Shankar Musunuri, Ocugen's CEO, emphasized Vu's strong business background and its alignment with the company's long-term strategy. Previously, Vu served as COO/CBO for 180 Life Sciences and has held high-level roles at various pharmaceutical companies. This leadership change is seen as essential for Ocugen's growth, especially as they advance their gene therapy pipeline.

Ocugen, Inc. (NASDAQ: OCGN) announced that Dr. Shankar Musunuri, the Chairman and CEO, will present at the BIO CEO & Investor Conference from February 6-9, 2023, in New York City. The event will showcase Ocugen’s business strategy, recent achievements, and future milestones through one-on-one meetings with potential investors and pharmaceutical companies.

Details of the presentation include:

• Event: BIO CEO & Investor Conference
• Date: February 6, 2023
• Time: 11:00 a.m. ET
• Location: Marriott Marquis, Winter Garden Room

Participants can register via the BIO CEO attendee portal.

Ocugen (NASDAQ: OCGN) announced positive results from its Phase 2/3 study of COVID-19 vaccine candidate COVAXIN™, showing it met both co-primary endpoints with strong immune responses. The vaccine was well-tolerated among participants, including those previously vaccinated with mRNA vaccines, with no serious adverse events reported. The study involved 419 adults in the U.S., demonstrating that COVAXIN™ generates a broader immune response against COVID-19 compared to standard vaccines. The results bolster Ocugen's plans for further development and emergency use authorization in the U.S.

Ocugen, Inc. announced the FDA's approval of its Phase 3 study design for NeoCart®, a regenerative cell therapy aimed at repairing knee cartilage lesions in adults. This crucial step follows their pipeline expansion initiative from May 2022. The randomized trial seeks to demonstrate NeoCart's superiority over existing treatments. Additionally, Ocugen is establishing a Good Manufacturing Practice facility and aims to file an Investigational New Drug amendment by late 2023 or early 2024. The FDA previously designated NeoCart® as a regenerative medicine advanced therapy.

Ocugen announced the FDA has granted orphan drug designation to OCU400 for treating retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA). This designation highlights the potential of OCU400, a nuclear hormone-based gene therapy, in addressing rare inherited retinal diseases that currently lack treatment options. Approximately 110,000 people in the U.S. are affected by RP, and 10,000 by LCA. The company aims to advance OCU400 through clinical development, providing hope for affected patients.

Ocugen, Inc. (NASDAQ: OCGN) will ring the Nasdaq Closing Bell on December 19, 2022, to celebrate its 2022 achievements and discuss future clinical and regulatory goals. CEO Dr. Shankar Musunuri emphasized the company’s innovative approach, particularly its modifier gene therapy for retinal diseases and COVID-19 vaccine technologies. Ocugen aims for Biologics License Application filings or product launches annually for the next five years, showcasing its commitment to 'Courageous Innovation.'